Literature DB >> 23775979

In vivo radioligand binding to translocator protein correlates with severity of Alzheimer's disease.

William C Kreisl1, Chul Hyoung Lyoo, Meghan McGwier, Joseph Snow, Kimberly J Jenko, Nobuyo Kimura, Winston Corona, Cheryl L Morse, Sami S Zoghbi, Victor W Pike, Francis J McMahon, R Scott Turner, Robert B Innis.   

Abstract

Neuroinflammation is a pathological hallmark of Alzheimer's disease, but its role in cognitive impairment and its course of development during the disease are largely unknown. To address these unknowns, we used positron emission tomography with (11)C-PBR28 to measure translocator protein 18 kDa (TSPO), a putative biomarker for inflammation. Patients with Alzheimer's disease, patients with mild cognitive impairment and older control subjects were also scanned with (11)C-Pittsburgh Compound B to measure amyloid burden. Twenty-nine amyloid-positive patients (19 Alzheimer's, 10 mild cognitive impairment) and 13 amyloid-negative control subjects were studied. The primary goal of this study was to determine whether TSPO binding is elevated in patients with Alzheimer's disease, and the secondary goal was to determine whether TSPO binding correlates with neuropsychological measures, grey matter volume, (11)C-Pittsburgh Compound B binding, or age of onset. Patients with Alzheimer's disease, but not those with mild cognitive impairment, had greater (11)C-PBR28 binding in cortical brain regions than controls. The largest differences were seen in the parietal and temporal cortices, with no difference in subcortical regions or cerebellum. (11)C-PBR28 binding inversely correlated with performance on Folstein Mini-Mental State Examination, Clinical Dementia Rating Scale Sum of Boxes, Logical Memory Immediate (Wechsler Memory Scale Third Edition), Trail Making part B and Block Design (Wechsler Adult Intelligence Scale Third Edition) tasks, with the largest correlations observed in the inferior parietal lobule. (11)C-PBR28 binding also inversely correlated with grey matter volume. Early-onset (<65 years) patients had greater (11)C-PBR28 binding than late-onset patients, and in parietal cortex and striatum (11)C-PBR28 binding correlated with lower age of onset. Partial volume corrected and uncorrected results were generally in agreement; however, the correlation between (11)C-PBR28 and (11)C-Pittsburgh Compound B binding was seen only after partial volume correction. The results suggest that neuroinflammation, indicated by increased (11)C-PBR28 binding to TSPO, occurs after conversion of mild cognitive impairment to Alzheimer's disease and worsens with disease progression. Greater inflammation may contribute to the precipitous disease course typically seen in early-onset patients. (11)C-PBR28 may be useful in longitudinal studies to mark the conversion from mild cognitive impairment or to assess response to experimental treatments of Alzheimer's disease.

Entities:  

Keywords:  Alzheimer’s disease; mild cognitive impairment; neuroinflammation; positron emission tomography

Mesh:

Substances:

Year:  2013        PMID: 23775979      PMCID: PMC3692038          DOI: 10.1093/brain/awt145

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  54 in total

1.  Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain.

Authors:  Bruce Fischl; David H Salat; Evelina Busa; Marilyn Albert; Megan Dieterich; Christian Haselgrove; Andre van der Kouwe; Ron Killiany; David Kennedy; Shuna Klaveness; Albert Montillo; Nikos Makris; Bruce Rosen; Anders M Dale
Journal:  Neuron       Date:  2002-01-31       Impact factor: 17.173

2.  Automatically parcellating the human cerebral cortex.

Authors:  Bruce Fischl; André van der Kouwe; Christophe Destrieux; Eric Halgren; Florent Ségonne; David H Salat; Evelina Busa; Larry J Seidman; Jill Goldstein; David Kennedy; Verne Caviness; Nikos Makris; Bruce Rosen; Anders M Dale
Journal:  Cereb Cortex       Date:  2004-01       Impact factor: 5.357

3.  Amyloid-β imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods.

Authors:  Susan M Landau; Christopher Breault; Abhinay D Joshi; Michael Pontecorvo; Chester A Mathis; William J Jagust; Mark A Mintun
Journal:  J Nucl Med       Date:  2012-11-19       Impact factor: 10.057

4.  Seizure-induced brain-borne inflammation sustains seizure recurrence and blood-brain barrier damage.

Authors:  Laura Librizzi; Francesco Noè; Annamaria Vezzani; Marco de Curtis; Teresa Ravizza
Journal:  Ann Neurol       Date:  2012-07       Impact factor: 10.422

5.  Aβ-amyloid deposition in patients with Parkinson disease at risk for development of dementia.

Authors:  Myria Petrou; Nicolaas I Bohnen; Martijn L T M Müller; Robert A Koeppe; Roger L Albin; Kirk A Frey
Journal:  Neurology       Date:  2012-08-29       Impact factor: 9.910

Review 6.  Mild cognitive impairment as a diagnostic entity.

Authors:  R C Petersen
Journal:  J Intern Med       Date:  2004-09       Impact factor: 8.989

7.  Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.

Authors:  G McKhann; D Drachman; M Folstein; R Katzman; D Price; E M Stadlan
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

8.  A genetic polymorphism for translocator protein 18 kDa affects both in vitro and in vivo radioligand binding in human brain to this putative biomarker of neuroinflammation.

Authors:  William C Kreisl; Kimberly J Jenko; Christina S Hines; Chul Hyoung Lyoo; Winston Corona; Cheryl L Morse; Sami S Zoghbi; Thomas Hyde; Joel E Kleinman; Victor W Pike; Francis J McMahon; Robert B Innis
Journal:  J Cereb Blood Flow Metab       Date:  2012-09-12       Impact factor: 6.200

9.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B.

Authors:  William E Klunk; Henry Engler; Agneta Nordberg; Yanming Wang; Gunnar Blomqvist; Daniel P Holt; Mats Bergström; Irina Savitcheva; Guo-feng Huang; Sergio Estrada; Birgitta Ausén; Manik L Debnath; Julien Barletta; Julie C Price; Johan Sandell; Brian J Lopresti; Anders Wall; Pernilla Koivisto; Gunnar Antoni; Chester A Mathis; Bengt Långström
Journal:  Ann Neurol       Date:  2004-03       Impact factor: 10.422

Review 10.  Inflammatory processes in Alzheimer's disease.

Authors:  Edith G McGeer; Patrick L McGeer
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2003-08       Impact factor: 5.067

View more
  141 in total

Review 1.  Molecular Imaging of Neuroinflammation in HIV.

Authors:  Anna Boerwinkle; Beau M Ances
Journal:  J Neuroimmune Pharmacol       Date:  2018-12-05       Impact factor: 4.147

2.  Imaging robust microglial activation after lipopolysaccharide administration in humans with PET.

Authors:  Christine M Sandiego; Jean-Dominique Gallezot; Brian Pittman; Nabeel Nabulsi; Keunpoong Lim; Shu-Fei Lin; David Matuskey; Jae-Yun Lee; Kevin C O'Connor; Yiyun Huang; Richard E Carson; Jonas Hannestad; Kelly P Cosgrove
Journal:  Proc Natl Acad Sci U S A       Date:  2015-09-18       Impact factor: 11.205

3.  The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations.

Authors:  E Cavedo; S Lista; Z Khachaturian; P Aisen; P Amouyel; K Herholz; C R Jack; R Sperling; J Cummings; K Blennow; S O'Bryant; G B Frisoni; A Khachaturian; M Kivipelto; W Klunk; K Broich; S Andrieu; M Thiebaut de Schotten; J-F Mangin; A A Lammertsma; K Johnson; S Teipel; A Drzezga; A Bokde; O Colliot; H Bakardjian; H Zetterberg; B Dubois; B Vellas; L S Schneider; H Hampel
Journal:  J Prev Alzheimers Dis       Date:  2014-12

4.  Inflammation in the Neurocircuitry of Obsessive-Compulsive Disorder.

Authors:  Sophia Attwells; Elaine Setiawan; Alan A Wilson; Pablo M Rusjan; Romina Mizrahi; Laura Miler; Cynthia Xu; Margaret Anne Richter; Alan Kahn; Stephen J Kish; Sylvain Houle; Lakshmi Ravindran; Jeffrey H Meyer
Journal:  JAMA Psychiatry       Date:  2017-08-01       Impact factor: 21.596

5.  (11)C-PBR28 imaging in multiple sclerosis patients and healthy controls: test-retest reproducibility and focal visualization of active white matter areas.

Authors:  Eunkyung Park; Jean-Dominique Gallezot; Aracely Delgadillo; Shuang Liu; Beata Planeta; Shu-Fei Lin; Kevin C O'Connor; Keunpoong Lim; Jae-Yun Lee; Anne Chastre; Ming-Kai Chen; Nicholas Seneca; David Leppert; Yiyun Huang; Richard E Carson; Daniel Pelletier
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-04-02       Impact factor: 9.236

6.  Effect of Cigarette Smoking on a Marker for Neuroinflammation: A [11C]DAA1106 Positron Emission Tomography Study.

Authors:  Arthur L Brody; Robert Hubert; Ryutaro Enoki; Lizette Y Garcia; Michael S Mamoun; Kyoji Okita; Edythe D London; Erika L Nurmi; Lauren C Seaman; Mark A Mandelkern
Journal:  Neuropsychopharmacology       Date:  2017-03-06       Impact factor: 7.853

Review 7.  [Neuroinflammation as motor of Alzheimer's disease].

Authors:  Sergio Castro-Gomez; Julius Binder; Michael T Heneka
Journal:  Nervenarzt       Date:  2019-09       Impact factor: 1.214

Review 8.  Future Directions in Imaging Neurodegeneration.

Authors:  Joseph C Masdeu
Journal:  Curr Neurol Neurosci Rep       Date:  2017-01       Impact factor: 5.081

Review 9.  In vivo PET imaging of neuroinflammation in Alzheimer's disease.

Authors:  Julien Lagarde; Marie Sarazin; Michel Bottlaender
Journal:  J Neural Transm (Vienna)       Date:  2017-05-17       Impact factor: 3.575

10.  Cerebellum Can Serve As a Pseudo-Reference Region in Alzheimer Disease to Detect Neuroinflammation Measured with PET Radioligand Binding to Translocator Protein.

Authors:  Chul Hyoung Lyoo; Masamichi Ikawa; Jeih-San Liow; Sami S Zoghbi; Cheryl L Morse; Victor W Pike; Masahiro Fujita; Robert B Innis; William Charles Kreisl
Journal:  J Nucl Med       Date:  2015-03-12       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.